ry approval of a medical device, and regulatory approval in turn does not guarantee insurance coverage. Furthermore, regulatory or reimbursement approval does not address questions regarding the evidence for analgesic efficacy. In this article, we report our findings on the quality of evidence that supports the use of four neurostimulation therapies to treat chronic pain: SCS for painful low-back disorders and CRPS, DBS for nociceptive or neuropathic pain, MCS for neuropathic and central pain, and ONS for occipital neuralgia and transformed migraine headaches. Issues of safety and animal experiments are excluded from our analysis, as are stimulation therapies that involve other indications or neural targets.
Clinical Material and Methods

Background Information
The results of experiments conducted in the 1950s and 1960s led investigators to stimulate the ventral posterolateral and posteromedial sensory thalamic nuclei and/or the PAG and PVG in patients with chronic intractable pain. 46, 50, 73, 83, 107, 117 The gate theory also prompted investigators to stimulate the dorsal columns of the spinal cord for chronic segmental or radicular pain, particularly after multiple lumbar spine operations. 76, 116 Reports of analgesic effects after MCS appeared in the 1980s and 1990s. 25, 44, 53 Thereafter, authors of case series and reviews described optimistic results for each modality. In 1976, the US FDA asserted authority over the regulation of implantable medical devices, and in the 1980s, the FDA reviewed implantable neurostimulation devices. On the basis of available publications and expert testimony, the FDA ruled that spinal cord and peripheral nerve stimulation devices could continue to be marketed in the US without formal clinical trials of efficacy. Subsequent approvals of newer-generation devices were based on limited safety and usability trials as well as other provisions of the Code of Federal Regulations. 32 In contrast, because the FDA ruled that DBS leads were substantial-risk investigational devices, new implantations in the US could proceed only in approved clinical trials or by compassionate use. The FDA's approval of the Activa DBS system (Medtronic, Inc., Minneapolis, MN) for medically refractory tremor in 1997, Parkinson disease in 2002, and dystonia (humanitarian use) in 2003, made DBS devices available again for the treatment of pain, but as an unlabeled indication for an approved device. Although DBS therapy for pain is not covered by all medical insurance plans in the US, the same family of devices has been continuously available in other countries. Investigators continue to express interest in DBS as well as newer stimulation sites, techniques, and devices. 4, 33, 108 Other examples of unlabeled indications include MCS for central, neuropathic, or deafferentation pain, and ONS for headache disorders. At present, MCS is, in fact, unlabeled for any indication in the US. A clinical trial of MCS for pain commenced in Europe in 2005, and a clinical trial of ONS using leads approved for SCS is in progress in the US. Our hypothesis, based on the work described in this article, is that a positive reporting bias in the clinical literature, combined with the nature of chronic pain, has created a mismatch between the expectations of patients and physicians, and the findings of a structured analysis of the clinical literature.
Data Sources
We identified relevant publications using the US National Library of Medicine PubMed database and the following search terms: "spinal cord stimulation-," "deep brain stimulation-," "motor cortex stimulation-," and "occipital nerve stimulation AND pain." Search limits included "language = English" (or an English-language abstract) and "human." We identified additional historical references from the bibliographies of indexed publications and reviews. Publications including clinical efficacy information were selected for detailed analysis of the features listed in Table 1 . 17, 139 We focused our analysis of SCS on 20 publications containing clinical efficacy data (from among 1334 indexed citations between June 1, 1994 and March 31, 2004) . One controlled, randomized, blinded study of SCS published before 1994 but not cited in any other published reviews was also included in our analysis. 69 The June 1994 search limit corresponds to the cut-off date for a structured review of the literature on SCS for low-back and radicular leg pain by Turner, et al. 133 One of us recently reported the results of two multicenter clinical trials of DBS for pain and performed a structured review of the pertinent literature. 24 In the present study, we build on that analysis and examine DBS efficacy for pain in seven published case series or reports (from among 44 citations) that had appeared between the December 1999 cut-off date for the previous review and the March 31, 2004 cut-off date for the present article. Motor cortex stimulation for intractable neuropathic or central pain and ONS for headache disorders are recently introduced therapies; therefore we used no initial time limit for this topic's search strategy. We evaluated 33 clinical reports (from among 168 citations) and four publications (from among 20 citations) in which the authors described the efficacy of MCS and ONS, respectively.
Results
Success Criteria and Reported Efficacy Rates
A historically accepted success criterion in neurostimulation studies of pain is that 50% or more patients should report 50% or greater pain relief (PPR Ն 50% reduction in the VAS of pain intensity) on follow-up evaluation, usually 6 to 24 months after treatment. Until recently, minor variations of the 50:50 standard have been used in most trials and studies. 14, 24 By definition and to prevent a few cases from skewing the results, average or aggregate reductions in pain ratings were not previously used to calculate efficacy rates.
In 1995, Turner, et al., 133 tabulated a mean success rate of 59% of patients with 50% or greater pain relief among 20 retrospective cases of SCS for low-back pain. Recent studies of SCS for low-back pain also yielded statistically significant aggregate or average pain relief scores compared with baseline scores. Based on a single-center study, Burchiel, et al., 14 reported a mean pain reduction of 45.6 Ϯ 31.9% (mean Ϯ standard deviation) 3 months after treatment. In a larger, 1-year multicenter study that included all of the single-center patients just mentioned, investigators reported a mean pain reduction of 47 Ϯ 27%. 13 Another study of SCS in patients with low-back pain by Ohnmeiss, et al., 95 revealed a 6-week posttreatment mean pain reduction of 43% and 2-year posttreatment mean pain reduction of 15%. Sindou and colleagues 118 reported an aggregate success rate (Ն 50% pain relief) of 54.7% in 95 patients with pain attributable to various causes. North and associates 93 performed a long-term, prospective, randomized comparison of SCS and reoperation in persons with persistent pain after back surgery. The primary indicator of success was the number of patients who after undergoing their randomly assigned procedure, requested to cross over to the other treatment group. That study was not designed to measure the degree of pain relief afforded by SCS, although the results revealed a significant advantage of that treatment modality compared with conventional reoperation. Other authors have reported limited efficacy for novel SCS programs to treat pain in the low-back region, have compared different SCS lead designs, or have lacked sufficient data to draw conclusions about long-term procedural efficacy. 7, 59, 104, 119, 136 All of the studies we reviewed had open label designs and involved a comparison between a patient's posttreatment condition and his or her own baseline. No author has reported 50% or greater long-term pain relief in 50% or more patients unless efficacy was analyzed without regard for the duration of the follow-up evaluation and/or unless patients who had been lost to, or disqualified from, follow-up analysis were excluded from the calculations.
In a 2004 review, Turner, et al., 134 found one randomized controlled trial among 583 articles on SCS for RSD or CRPS. 57, 71 Although in that study patient pain was statistically significantly reduced 24 months after SCS plus physical therapy compared with physical therapy alone, the effect size did not reach the 50:50 standard. Other reports on the efficacy of SCS for CRPS or peripheral neuropathic pain have consisted of retrospective series or case reports, were focused on the predictive value of preoperative pharmacological screening, or have included patients who have undergone multiple simultaneous therapies including SCS, peripheral nerve stimulation, and intraspinal drug delivery, in various combinations. 1, 15, 28, 49, 61, 62 Marchand and colleagues studied the efficacy of SCS in a randomized, blinded, controlled laboratory and clinical investigation of eight patients who had experienced a mean self-reported pain relief of 63% after at least 2 years of therapy. 69 Each patient's customary stimulator settings were used in the laboratory and clinical phases as the active treatment arm, and sham stimulation with the amplitude off served as the control. According to these investigators, "All patients reported a sensation, when in fact no stimulation was given" during the control phase. Laboratory assessments involved the use of standard thermal stimuli presented in random order during the active therapy and control states. The mean difference between active SCS and sham stimulation in the experimental pain intensity and unpleasantness dimensions was 20 to 28%, depending on whether the measurement was taken during, or immediately after, the stimulation session. Spinal cord stimulation also increased the heat tolerance threshold by 0.5˚C. Clinical assessments were performed during separate sessions for the active and sham treatment conditions. The effect size of active compared with sham SCS on clinical pain intensity and unpleasantness was 23 and 30%, respectively.
In all DBS clinical series, fewer patients reported pain relief after 6 to 24 months of therapy compared with the early postimplant period, and no study demonstrated the 50:50 success level unless short-term results carried the same analytical weight as the results of follow-up evaluations that 24 The resin-coated wire DBS lead used in the first trial (196 patients) became obsolete and was withdrawn from the market; a trial (50 patients) of the currently used model of DBS lead was closed because of slow enrollment and unexpectedly low rate of therapeutic efficacy. 24 More recently, Nandi, et al., [84] [85] [86] reported that seven patients with internalized DBS systems (among eight with implanted electrodes) experienced 32 to 46% pain relief 3 to 30 months after treatment. [84] [85] [86] Other authors have reported pain relief nonquantitatively, described cerebral blood flow measurements without addressing efficacy, or described the onset of new pain syndromes after DBS surgery. 63, 99, 135 Marchand and colleagues 71 used methods similar to those in their investigation of SCS to study the effects of thalamic DBS under randomized, blinded, and controlled conditions in six patients who had reported pain relief for at least 2 years after implantation (mean PPR 53.3%). The placebocontrolled eight-day clinical home rating phase revealed a mean 10% effect size for active stimulation compared with placebo, whereas laboratory trials using nociceptive thermal stimuli demonstrated a 16% effect size for pain intensity and a 4% effect size for unpleasantness.
No large-scale blinded and controlled trials of MCS have been completed to date, although two centers performed blinded studies on subsets of patients who reported efficacy (Meyerson, et al., one patient; Smith, et al., two patients). 79, 120 Several authors reported efficacy after chronic MCS in selected patients who had experienced pain relief during a trial stimulation period (Table 2) . Note, however, that reported outcome categories that were nonquantitative or spanned the 50% PPR or VAS level made it impossible to determine whether the results in several reports reached the 50:50 success level. 12, 34, 52, 54, [87] [88] [89] [90] 113, 114, 131, 132 Furthermore, patients in one study experienced a PPR of 50% or more while at rest but not during activity. 110, 121 Pooled results from publications with sufficient data to assess the 50:50 efficacy standard revealed an aggregate success rate of 59% (56 of 95 cases). 20, 22, 29, 34, 37, 47, 52, 55, 56, 79, 80, 82, 91, 98, 105, 109, 110, [120] [121] [122] 132, 141 If one assigns the ambiguously reported cases to either a successful or an unsuccessful result, the proportion of patients who experienced 50% or greater pain relief varied from a hypothetical best-case scenario of 65% (95 of 146 cases) to a worst-case scenario of 56% (82 of 146 cases). 36, 54, 78, [87] [88] [89] 113, 114, 130, 131 Success rates in two recent case series of ONS for head pain disorders were 64.5 and 100% during a mean follow up of 18 months. 102, 138 In a report of 25 cases, nine (36%) patients still experienced moderately or severely disabling headaches 9 to 36 months after treatment. 102 The Neurostimulation Literature Nature of the Reports. Evidence-related features of the recent clinical literature on neurostimulation are listed in detail in Table 2 and summarized in Table 3 ; both tables are organized according to published criteria for the evaluation of medical evidence. 17, 139 Authors of a few studies, some of which were reported in multiple publications, described eight prospective series for SCS, 5, 13, 57, 71, 93, 95, 118, 119 two for DBS, including the US clinical trials, 24, [84] [85] [86] and two for MCS. 22, 78, 120 The prospective studies of SCS for RSD and of SCS compared with reoperation for low-back pain each made use of control groups and randomization. Note, however, that patients and evaluators were not blinded because control-arm participants in the RSD trial and patients with spinal pain who had undergone reoperation in the low-back pain trial did not receive SCS devices. 57, 58, 93 The Marchand and colleagues' 69,71 studies of patients with previously implanted SCS and DBS devices were controlled, randomized, and double-blinded. The remainder of neurostimulation publications consisted of retrospective case series, case reports, or meeting abstracts. Although the studies analyzed here yielded valuable data, none were intended to be formal trials for regulatory approval or to establish standards of care.
Diagnoses and Patient Selection. Diagnoses, demographic data, number of eligible patients who were evaluated or excluded, pretreatment duration of pain, and previous pain therapies were reported unevenly or not at all in publications on all four neurostimulation modalities ( Table 2 ). The assignment of diagnoses or pain categories-including nociceptive, deafferentation, central, and mixed pain or headache disorders-was inconsistent among centers and sometimes among reports from the same institution. In one series, the occipital neuralgia diagnoses in a subset of patients treated successfully with ONS were subsequently revised to chronic or transformed migraine headache. 45, 72, 138 Published reports described selection criteria that were believed to maximize the likelihood of success, including pain in contiguous regions that could be covered by stimulation-induced paresthesias, favorable responses to transcutaneous electrical nerve stimulation, diseases previously reported to respond favorably to treatment, and rejection of patients with suspected unfavorable psychological or personality profiles, drug addiction, or pending litigation. 15, 20, 28, 49, 54, 61, 62, 72, 80, 92, 100, 106, 113, 114, 122, [130] [131] [132] 136, 138, 141 In other reports, the results of psychological or pharmacological screening were not reported or had little influence on whether patients were accepted for therapy. 12, 22, 24, 36, 37, 55, 56, 78, 79, 82, 89, 90, 98, 109, 110, 121 Stimulation Targets, Test Simulation, and Ancillary Treatments. The neural targets for SCS were the dorsal columns of the spinal cord at the cervical or thoracic levels to treat upper-or lower-extremity pain, respectively, and by using percutaneous or surgically implanted epidural leads. Deep brain stimulation targets included the ventral posterolateral and posteromedial thalamic nuclei, the PAG and PVG regions, or all, depending on the surgeon's judgment, the patient's symptoms, and the results of preoperative screening tests. Lead implantation techniques for MCS evolved during the 1990s to include neuroimaging guidance in addition to electrophysiological localization tests. Note that some reports spanned the period when epidural lead placement supplanted subdural lead placement. 12, 36, 37, 78, 88, 89 Implanters at one institution used external landmarks to plan the craniotomy and monitored intraoperative responses during second-stage awake surgery to position the MCS leads. 22, 120 Occipital nerve stimulation involved percutaneous fluoroscopy-guided insertion of SCS leads into the subcutaneous tissue at the C-1 level. A transverse trajectory resulted in the placement of the electrical contact surfaces across the course of the greater and lesser occipital nerves. For all neurostimulation therapies, the use or duration of a trial period before system internalization, the methods used to select ac- ing, and Analysis. Seven studies of SCS and six studies of MCS involved the use of independent or quasi-independent evaluators (Table 2 ). However, the implanters or their associates-that is, persons aware of a patient's history and previous assessments and responsible for his or her ongoing care-performed the follow-up evaluations in all other series. The duration of the follow-up period often was unclear, not reported, or varied from months to years within the same series. Multiple reports of the same patient cohort frequently did not track individual cases through the series of publications. Because follow-up periods were not uniform within most series, because 30 to 68% of patients across reported series did not comply with the long-term followup protocol, and because life-table analyses were not performed, different durations of therapy carried equal weight in efficacy calculations. 51 The studies that had well-defined follow-up periods ( Table 2 , "uniform timing reported") consisted of 11 published SCS series for low-back pain or RSD, two industry-sponsored DBS lead trials, six MCS series, and the experimental studies of SCS and DBS by Marchand and colleagues. 69, 71 Methods for assessing efficacy included the VAS, PPR, and other standardized or nonstandardized scales and categories. The two DBS trials that ended in 1995 were the last to include a prospectively defined criterion for success, requiring 50% or more of the patients with internalized devices to report 50% or greater pain relief after a prospectively defined interval of 1 to 2 years. Authors of subsequent reports on neurostimulation efficacy either sought statistically significant differences in aggregate pain relief scores (PPR or VAS) compared with baseline values or used descriptive outcome categories that spanned the 50% PPR or VAS value.
Previous Reviews. Authors of four reviews and one editorial addressing SCS efficacy over the past 10 years provided a critical analysis of this therapy's efficacy for low-back pain, CRPS, or spinal cord injury pain. 41, 67, 133, 134, 137 Four of these five publications were from one group of investigators. A structured review of DBS by Duncan and associates, 27 another review by one of the present authors (R.J.C.), 24 and a cautious assessment of MCS by Smith and colleagues 120 provided critical analyses of these therapies. Authors of other recent reviews, including those contained within case series, recapped previously reported results without analyzing the nature of the evidence regarding efficacy claims for SCS, Experience with ONS is preliminary; authors of one review article cited a single clinical report. 125 Most reviewers accepted the hypothesis that neurostimulation provided pain relief as described in the original reports, and some limited the scope of their debate to technical details or to speculation about the mechanisms of stimulation-produced analgesia. 2, 8, 9, 38, 47, 81, 101 A shift away from prospectively defined success thresholds (such as the 50:50 rule) in favor of statistical end points-namely, significant differences between baseline and posttreatment pain scores-has made structured reviews more difficult, especially when incomplete data are provided. Statistical difference-based end points also have prompted investigators to perform multivariate analyses of apparent correlations between statistically defined efficacy and underlying patient characteristics. It remains to be determined whether such analyses have revealed reliable prognostic factors that can be verified in larger controlled studies.
Discussion
The paradox of pain-its simultaneous reality and subjectivity-makes the assessment of pain relief therapies susceptible to observer-or patient-related influences. Unintentional cues, learned responses, or knowledge that a treating physician or a physician's representative is conducting the assessment can affect how patients rate analgesic treatments. Reliable methods of controlling for such influences are used in psychological and behavioral studies and should be applied to analyses of neurostimulation for pain. 27, 123 Because the use of control groups, blinding, randomization, or prospectively defined methods of analysis have revealed smaller analgesic effects than those reported in case series and uncontrolled trials, several common notions in the field of neurostimulation should be open to reexamination in future trials. Such notions include the prognostic value of diagnostic categories (nociceptive, deafferentation, or central pain); the utility of preimplantation screening by using psychological, personality, or pharmacological tests; and the value of temporary stimulation trials. Other factors to reevaluate are the disparities between short-and long-term results, including the concept of stimulation tolerance, and the possibility that efficacy can diminish over time because chronic pain syndromes worsen. Finally, it is worth examining whether reports and reviews of neurostimulation therapies reflect a bias toward positive interpretation of in- conclusive data-a phenomenon associated with new or emerging therapies. 126 
Diagnoses and Prognostic Factors
Patient selection factors are uniformly reported to influence the success of neurostimulation therapies. One fundamental selection criterion is the diagnosis or origin of a patient's pain. Summarized data in Table 2 indicate that individual diagnoses and broader diagnostic categories in the neurostimulation literature sometimes have been arbitrary (the same diagnosis is placed into different pain categories or contradictory diagnoses are assigned to the same pain category) or malleable (diagnoses revised in retrospect). Authors of a few recent trials have attempted to overcome this limitation by narrowly specifying diagnoses in the study protocols (for example, SCS for angina pectoris and MCS for central poststroke pain) and by requiring objective documentation of the diagnosis in each patient's medical records (for example, imaging studies and electrophysiological tests). Both factors-diagnostic consistency and assurance that each patient's diagnosis has a sound anatomical and physiological basis-are crucial to the successful investigation of neurostimulation therapies.
Another factor that may correlate with successful therapy is the integrity of neural tissue at the target stimulation region as revealed on imaging studies or inferred from results of the neurological examination or electrophysiological tests. It is logical to consider these factors given the use of neurophysiological techniques to localize the optimal stimulation site and the fact that therapy may be futile if the stimulation site has been destroyed by the same disorder that is causing the patient's pain. In contrast, available evidence does not support selection based on responses to analgesic or sedative drugs, or local anesthetic injections. Authors who have examined these factors describe small numbers of patients or studies that were not double-blinded. 18, 49, 52, 56, 72, 113, 130, 138, 141 Both are conditions that may misattribute predictive value to random fluctuations within small data sets and that may be susceptible to suggestibility. The hypothesis that pharmacological or local anesthetic responses influence the outcome of neurostimulation therapies can be tested on larger numbers of patients during future clinical trials.
Other selection criteria have been associated with the patient's medical history as well as demographic and psychosocial factors. Such factors have been evaluated in studies of SCS and reviewed in the DBS literature. 14, 24, 95 In Burchiel and colleagues' 14 study of SCS for low-back pain, results of a multivariate analysis revealed that the combination of patient age and his or her score on the McGill Pain Questionnaire's evaluative and depression subscales correlated with a 50% or greater reduction in VAS scores at 3 months postimplantation. However, one would expect variables that emerge from a multivariate analysis of a particular data set to correlate strongly with the end point that drove the analysis in the first place-namely, the 3-month VAS score. The investigators discussed their findings cautiously and observed that even careful prospective studies of psychological and demographic variables have limitations, especially those with a small sample: the cohort under study may not be representative of the at-large population with pain; unexamined factors might turn out to be as, or more, important than those examined; and findings in a small sample should be validated in a new, substantially larger cohort to test for predictive value.
14 In another SCS study by Ohnmeiss, et al., 95 a psychologist assessed patient responses during intraoperative trial stimulation. Pain scores 24 months after treatment were reduced by approximately 1 cm or less on the VAS scale (Ͻ 10% pain reduction)-a statistically significant result that may have had little clinical significance. Findings related to the influence of demographic or psychosocial variables in DBS series and clinical trials were also disparate and inconclusive. 24 Comparable analyses of predictive factors have not been performed for MCS and ONS. The most significant limitation of previous analyses is the fact that the influence of putative prognostic factors cannot be measured if those same factors are used as inclusion or exclusion criteria. Psychosocial and demographic data should be collected in future trials, but patient inclusion based solely on having an eligible diagnosis, preserved anatomical substrate for stimulation, and no medical or surgical contraindications is one way to study the influence of psychological factors and other variables on longterm results.
Trial Stimulation and Blinded Programming
Temporary stimulation with externalized leads allows patients to experience stimulation-induced effects and physicians to adjust parameters to minimize unpleasant side effects and can preclude further investment in a therapy that may not match a patient's needs. In actual clinical practice, trial stimulation can influence patients to respond in an affirmative manner, especially if they are instructed to identify the neurostimulation setting that provides the best pain relief from among the choices presented to them. Once patients undergo lead implantation and report any degree of analgesia, they may be susceptible to caregivers' expressions of approval and optimism. This phenomenon may explain in part why the proportion of patients who experience long-term relief after an initial stimulation trial for the same disorder in different series has varied from approximately zero to approximately 100%. 24, 79, 120, 130, 131 Patient and evaluator blinding, and the random or repeated presentation of different stimulation settings by a neutral individual (not the implanter or evaluator) can reduce the occurrence and effect of unintentional cues or suggestions. Given the elective nature of neurostimulation for chronic pain, strategies to minimize such influences during the trial period, including harmless deception, are feasible and ethically sound.
Expectations, Reporting Bias, and Short-Compared With Long-Term Efficacy
The use of neurostimulation therapies occurs in a context of optimism and positive expectations. 43 In clinical practice outside of a formal trial or study situation, physicians and patients expect previously reported treatment success effectively to translate into relief of chronic pain. In contrast, the phenomenon of therapeutic confusion occurs when investigators in a formal trial believe that the primary purpose for intervention is to help patients rather than to determine whether the therapy in question is safe and effective. The difference between the two attitudes and situations is not merely semantic because therapeutic confusion is the inverse of equipoise-an idealized mindset within which in-vestigators enlist the cooperation of patients in clinical trials to help answer important questions. In return, patients in clinical trials have the opportunity to receive a promising treatment that has a reasonable chance of being safe and beneficial.
The physician-patient relationship outside of a trial setting is also influenced by government or insurance regulations and social policies. Thus, many patients with pain are dependent on the physician's approval to obtain valuable benefits. Tangible benefits include the approval of disability and medical insurance coverage, an excused absence from or modification of work duties, renewal of analgesic drug prescriptions, and referrals for physical therapy or other ancillary treatments. An intangible benefit is the validation of a patient's illness status. The loss of approval brings the opposite factors into play (for example, making patients vulnerable to economic loss if physicians withdraw authorization for such benefits). Consequently, patients may interact with physicians in a manner that maximizes the likelihood that benefits will continue. In contrast, patients who seek physician approval to continue insurance or unemployment payments, narcotic prescriptions, and other benefits after failing to report pain relief from neurostimulation (or other) therapies risk being labeled as manipulative or as having a nonorganic disorder. The cycle of expectations and responses is a feature of human behavior that is observed in a variety of situations; 123 it can cause caregivers and patients to reinforce each other's beliefs and should not to be confused with, or dismissed as, a placebo effect. 27 The same phenomenon may account for patients' more positive, subjective expressions of perceived global effects and satisfaction with therapy compared with their ratings of pain scores (VAS and PPR) in clinical trials. 71 Such ordinary behavioral and cognitive phenomena were among the reasons for using control groups and blinding in neurostimulation trials for multiple sclerosis and cerebral palsy during the 1970s and 1980s, and in other medical research as long as 50 to 250 years ago. 40, 65, 74, 96, 97, 142 Selective or multiple reporting of the same patient cohort has involved the choice of which pain syndromes, targets, or other data to publish. This process has influenced the reported success rate of neurostimulation therapies and has contributed to the difficulty we encountered in tracking individual cases through serial publications (Table 2 ). Authors of recent editorials have identified the loss of patients to follow-up evaluation as another factor that limits the interpretation of long-term therapeutic efficacy in published studies of other pain relief modalities. 35 The assignment of patient outcomes by individuals with a stake in a particular therapy's success may have also influenced success rates. In the literature that we reviewed, no one has explained why efficacy appears to diminish over time or why patient selection and screening methods have not increased the long-term efficacy rate of neurostimulation therapies over the past few decades. Such questions can be prospectively addressed in future trials or studies.
Clinical Trial Design Recommendations
New data and, most likely, patients with newly implanted devices will be required if researchers wish to analyze new hypotheses and commonly held notions about neurostimulation for pain relief. Data mining or performing metaanalyses of currently available data will not provide accurate answers. Furthermore, because much of the available efficacy data were collected under uncontrolled conditions or as retrospective analyses of clinical practices, additional data collected under similar conditions cannot make up for deficits in the existing knowledge base. To make a fresh start and to quantify the effects of neurostimulation, authors of new clinical investigations should consider the methods for evaluating medical evidence (as summarized in Table  1) , and should include as many features as possible from Table 4 . Even formal compliance with Level I criterianamely, the randomization of patients and the presence of a control group-may yield data subject to significant limitations. Unintentional study design loopholes can include lack of blinding, ineffective blinding, and/or the selection of qualitatively different treatments for the active treatment compared with control arms (implantation compared with no implant, or substantially different treatments).
Trial protocols should specify a quantitative, validated, and prospectively defined success criterion that incorporates a particular effect size, such as the 50% better efficacy (or another specified percent) compared with the rate in a matched control group. Broad rather than enriched patient populations should be considered. Psychosocial screening tests or drug injections may be administered to potential patients, but the results should not disqualify candidates who have an eligible diagnosis. Broad inclusion and limited exclusion criteria would provide an opportunity to study the effects of therapy at different stages in the evolution of pain syndromes-another factor that may have prognostic value.
Persons with pain who have been recruited as patients in a controlled trial must accept the possibility of being assigned to a sham or nonoptimized treatment arm for a defined period after device implantation. Note, however, that they would receive active therapy once the blinded study period was finished. One cannot overemphasize the importance of Marchand and colleagues' [69] [70] [71] findings in studies of SCS, DBS, and transcutaneous electrical nerve stimulation (all of which produce paresthesias); that is, patients and evaluators can be blinded using straightforward and ethical methods. [69] [70] [71] Furthermore, investigators should make a sincere effort to refrain from nonstudy use of the therapy under investigation, so as not to bias the study population according to geography, insurance coverage, or other nonmedical factors.
Investigators and institutional review boards may debate the ethical ramifications of whether control-arm patients should receive no stimulation, subthreshold stimulation, or sham (deliberately nonoptimized) stimulation. 67 The best answer will depend on the specific hypothesis and stimulation modality under investigation, and multiple studies or multiarm trials may be required. One could argue that an equally important ethical issue is the settling of questions about efficacy as accurately and as harmlessly as possible. Having an adequately blinded control group for a sufficient duration of time is essential to that task. One method of integrating the optimization of stimulation parameters into a blinded, randomized trial and determining the contribution of therapy optimization methods to therapy effect size is to keep patients blinded to stimulation settings during the optimization period. This period should replicate the customary clinical practice for each modality, usually days to weeks. Therapy optimization should be followed by a stimulation-off interval of at least several days or weeks before starting the blinded study period. A time lapse allows for the following: a washout of any potential carryover effects into the blinded period, patients and investigators to forget experiences that may have compromised the blind during the optimization period, and an independent central office to process pain-relief and paresthesia mapping data (if applicable) before patient randomization. In this example, a central office then could send randomized individual patient assignments back to the study centers in sealed, numbered envelopes or a computer-based message. A patient randomized to receive active therapy would start the blinded study period at the optimal settings contained in the first envelope or message. A person randomized to ineffective therapy would start the blinded phase at the settings contained in the first envelope, and these stimulation parameters would elicit paresthesias or side effects similar to those induced by the effective settings but would not be associated with optimal pain relief. If the trial contained a sham or subthreshold stimulation arm, harmless deception regarding the settings would be required while the amplitude was set to zero voltage ("You may just barely feel something"). This tripleblind design allows patients, evaluators, and even the device programmer to remain blinded to any association between the prescribed settings in each patient's envelope and pain relief during the previous optimization period. Variations are adaptable to different study designs. A three-arm study, for example, could be set up as a comparison of optimal stimulation and sham stimulation (zero or subthreshold voltage) and deliberately ineffective or nonoptimized stimulation. All patients would be offered optimized active therapy at the end of the blinded study period.
Despite differences in individual physiological responses to neurostimulation, including unwanted side effects, some uniformity in treatment protocols is desirable. Such uniformity may be limited to the daily stimulation cycle times (device on or off) or can include a specified range of permissible settings for other parameters. Although only limited analogies between electrical stimulation and drug therapies are possible, studying specific parameters or programs is one way to determine the effects of different doses of stimulation. Medication intake also should be monitored using pill counts and could be augmented by drug screening in patients who report the cessation or markedly reduced intake of opioid, sedative, psychoactive, or other testable drugs.
Finally, data analysis methods should be specified in advance, including decisions about which denominators to use in efficacy calculations. Nearly all stimulation series and trials involved patients who had undergone permanent device internalization. In a study that incorporates a test stimulation period with externalized leads, an intention-to-treat analysis (a strict method previously used by Tasker, et al. 127 ), will involve counting patients who undergo test stimulation but not device internalization as having zero long-term efficacy. Regardless of whether intention-to-treat methods were used, all patients in the control and treatment groups should be counted in the efficacy denominators.
Who Will Conduct Such Studies?
Spinal cord stimulation is approved in the US, European Union, and other jurisdictions, and its cost is reimbursed by many medical insurance plans. Although manufacturers are not required to conduct efficacy trials to market SCS devices for existing indications, one incentive for industry sponsorship may permit specific efficacy claims for new indications after successful trials. In contrast, investigators interested in studying existing therapies and indications most likely would have to seek funding from academic, governmental, or private foundation sources.
Data from open-label trials of thalamic or PAG/PVG DBS have already indicated the inefficacy of these treatments. 24 Unless promising new indications or target sites are developed, few incentives exist for industry to perform additional studies of traditional targets. Stimulation of the hypothalamus for intractable cluster headache is a new target for a new indication that may rekindle interest in DBS. 33 Given the small patient population that may benefit from such an intervention, investment beyond modest support for investigator-sponsored trials is unlikely in the near future.
Both MCS and ONS are recently introduced pain thera- 
Study Limitations
The authors applied clinical trial evaluation criteria that had been published between 1988 and 1990 to reports and reviews that had been published after 1994. Note, however, that sound methods for experimental design, analysis, and reporting (including neurostimulation studies) have been available for many years. Our finding that most published studies do not meet rigorous methodological and evidentiary standards does not mean that the treatments are ineffective, does not negate the positive experiences of patients, and does not detract from the value of previous investigations, which were not intended to establish standards of care or to support regulatory claims. Rather, we have shown that questions and hypotheses generated by analyses of existing data can only be answered by new data collected using investigational methods that are both feasible and as optimal as possible. As a corollary, the methodological features of most previous studies make it unlikely that additional metaanalyses of existing data will reveal new insights.
Conclusions
The neurostimulation therapies considered in this article involve various indications, anatomical sites, and proposed mechanisms of action. Still, a combined examination of the evidence is worthwhile because the similarities among the therapies outweigh the differences. An overlapping group of physicians is involved in the surgical decision-making process for each modality, and the therapies share common historical features. All of the treatments are based on plausible physiological hypotheses or data from experiments in laboratory animals, and all are associated with positive experiences among the treating physicians, high expectations among the patients, and positive reports and reviews in the medical literature. We believe that the study methods outlined in this paper can generate data that can be more robust than formal published criteria for Level I evidence. Well-designed studies are especially important to measure the efficacy of new and emerging neurostimulation treatments for chronic pain.
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